Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Bone and Calcium Disorders
Do you recommend initiating zoledronic acid for osteoporosis at the time of hospitalization for a fracture?
Related Questions
How do you approach diagnosis and management in patients with persistent hypercalcemia and elevated (but improved) PTH six months after parathyroidectomy for primary hyperparathyroidism?
Would you recommend waiting for a low Vitamin D level to correct to goal prior to giving a scheduled Prolia injection when transitioning a patient from Zolendronic acid to Prolia therapy for worsening osteoporosis?
Would elevated bone mineral density/T-score be enough to make a diagnosis of osteopetrosis?
What is the recommended duration of Burosumab therapy for treating X-linked hypophosphatemia and how is response to therapy monitored?
Do you temporarily hold diuretics when measuring 24-hour urine calcium levels in the evaluation of primary hyperparathyroidism?
Would you have concerns with continuing denosumab for much longer than the available ten year clinical safety trial data for an individual with renal insufficiency with persistent osteoporosis/history of compression fractures?
Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?
Should we aim to reduce or stop thiazides in patients with thiazide-induced hypercalcemia given its similar risk profile to untreated primary hyperparathyroidism?
Under what circumstances would you choose palopegteriparatide over teriparatide in patients with chronic hypoparathyroidism?
What is the recommended workup for PTH-independent hypercalcemia secondary to an elevated 1,25-dihydroxyvitamin D level?
